Cellular Mechanisms of Anti-Mycobacterial Immunity

  • Frank M. Collins
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 162)


Tuberculosis is an ancient human disease (1), which continues to be an important public health problem, despite the development of effective vaccines and chemotherapeutic agents. Widespread use of chemotherapy has dramatically reduced worldwide mortality rates for this disease, but has not yet been able to eliminate it (2). Approximately 28,000 new cases of pulmonary tuberculosis were reported in the United States last year, with nearly 3,000 deaths directly attributable to this disease (3,4). This continued high rate of incidence some 30 years after the development of potentially effective control measures is both surprising and disturbing. However, it is only when the problem of controlling this disease in Asia, Africa, and Central America is examined, where overcrowding, malnutrition and inadequate health delivery services contribute still further to its continued persistence, that the true dimensions of this world public health problem begin to emerge (5).


Pulmonary Tuberculosis Suppressor Cell Nontuberculous Mycobacterium Mycobacterium Bovis Lepromatous Leprosy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zimmerman, M. R. (1979). Pulmonary and osseous tuberculosis in an Egyptian mummy. Bull. N.Y. Acad. Med. 55:604–698.PubMedGoogle Scholar
  2. 2.
    Rouillon, A., Perdizet, S. and Parrott, R. (1976). Transmission of tubercle bacilli: the effect of chemotherapy. Tubercle. 57:275–299.PubMedCrossRefGoogle Scholar
  3. 3.
    Anon. (1979). “Annual Summary of Reported Morbidity and Mortality in the U.S.” Morb. Mort. Weekly Rep. 27:67–69.Google Scholar
  4. 4.
    Anon. (1981). Tuberculosis-United States. 1980. Morb. Mort. Weekly Rep. 30:55–56.Google Scholar
  5. 5.
    Holm, J. (1969). Tuberculosis in the world today. Bull. Intern. Union Tuberc. 43:26–33.Google Scholar
  6. 6.
    Lowell, A.M., Edwards, L.B. and Palmer, C.E. (1969). Tuberculosis. Harvard Press, Mass.Google Scholar
  7. 7.
    Wolinsky, E. (1979). Nontuberculous mycobacteria and associated diseases. Amer. Rev. Resp. Dis. 119:107–159.PubMedGoogle Scholar
  8. 8.
    Burjanova, B. and Urbancik, R. (1971). Experimental chemotherapy of mycobacteriosis provoked by atypical mycobacteria. Adv. Tuberc. Res. 17:154–188.Google Scholar
  9. 9.
    Corpe, R.F. (1964). Clinical aspects, medical and surgical, in the management of Battey-type pulmonary disease. Dis. Chest. 45:380–382.PubMedCrossRefGoogle Scholar
  10. 10.
    Marks, J. and Jenkins, P.A. (1971). The opportunistic mycobacteria: a 20 year retrospect. Postgrad. Med. 47:705–711.CrossRefGoogle Scholar
  11. 11.
    Kantor, F.S. (1975). Infection, anergy, and cell-mediated immunity. New Engl. J. Med. 292:629–634.PubMedCrossRefGoogle Scholar
  12. 12.
    Stead, W.W. (1978). Undetected tuberculosis in prison. J. Amer. Med. Assoc. 240:2544–2547.CrossRefGoogle Scholar
  13. 13.
    Lester, C.F. and Arve 11, R.J. (1958). The tuberculin skin reaction in active pulmonary tuberculosis. Amer. Rev. Tuberc; 78:399–402.Google Scholar
  14. 14.
    von Magnus, P., Eugbank, C.H. and Jespersen, A. (1967). Tuberculosis and BCG. Med. Clinics N, Amer. 51:753–764.Google Scholar
  15. 15.
    ten Dam, N.G., Toman, K., Hitze, K.L. and Guld, J. (1976), Present knowledge of immunization against tuberculosis. Bull. World Health Organ. 54:255–269.PubMedGoogle Scholar
  16. 16.
    Hart, D’A.P. (1967). The place of vaccination in tuberculosis control. Amer. Rev. Resp. Dis. 96:1–6.PubMedGoogle Scholar
  17. 17.
    Anon. (1980). Trial of BCG vaccines in South India for tuberculosis prevention: first report. Bull. Int. Union Tuberc. 55:14–20.Google Scholar
  18. 18.
    Comstock, G.W. and Edwards, P.Q. (1972). An American view of BCG vaccination illustrated by results of a controlled trial in Puerto Rico. Scand. J. Resp. Dis. 53:207–217.Google Scholar
  19. 19.
    Comstock, G.W. and Palmer, C.E. (1966). Long-term results of BCG vaccination in the Southern United States. Amer. Rev. Resp. Dis. 93:171–183.PubMedGoogle Scholar
  20. 20.
    Palmer, C.E. and Long, M.W. (1966). Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Amer. Rev. Resp. Dis. 94:554–568.Google Scholar
  21. 21.
    Eickhoff, T.C. (1977). The current status of BCG immunization against tuberculosis. Annual Rev. Med. 28:411–428.CrossRefGoogle Scholar
  22. 22.
    Dubos, R.J. and Pierce, C.H. (1956), Differential characteristics in vitro and in vivo of several substrains of BCG. IV. Immunizing effectiveness. Amer. Rev. Tuberc. 74:699–717.Google Scholar
  23. 23.
    Vallishayee, R.S., Shashidhara, A.N., Bunch-Christiansen, K, and Guld, J. (1974). Tuberculin sensitivity and skin lesions in children after vaccination with 11 different BCG strains. Bull. World Health Organ. 51:489–494.PubMedGoogle Scholar
  24. 24.
    Sher, M.A., Chaparas, S.D., Pearson, J. and Chirigos, M. (1973). Virulence of six strains of Mycobacterium bovis (BCG) in mice. Inf. Immun. 8:736–742.Google Scholar
  25. 25.
    Collins, F.M. and Miller, T.E. (1969). Growth of a drugresistant strain of Mycobacterium bovis (BCG) in normal and immunized mice. J. Infec. Dis. 120:517–533.CrossRefGoogle Scholar
  26. 26.
    Mackaness, G.B., Auclair, D.J. and Lagrange, P.H. (1973). Immunopotentiation with BCG. 1. Immune response to different strains and populations. J. Nat. Cancer Inst. 1655–1667.Google Scholar
  27. 27.
    Freudenstein, H., Pranter, W. and Schweinsberg, H. (1979). Assessment of several BCG vaccines in different animal test systems. J. Biol. Stand. 7:203–212.PubMedCrossRefGoogle Scholar
  28. 28.
    Ladefoged, A., Bunch-Christensen, K. and Guld, J. (1976). Tuberculin hypersensitivity in guinea pigs after vaccination with varying doses of BCG of 12 different strains. Bull. World Health Organ. 53:435–533.PubMedGoogle Scholar
  29. 29.
    Smith, D.W. and Harding, G.E. (1977). Approaches to the validation of animal test systems for assay of protective potency of BCG vaccines. J. Biol. Standard. 5:131–318.CrossRefGoogle Scholar
  30. 30.
    Wiegeshaus, E.H., Harding, G., McMurray, D., Grover, A.A. and Smith, D.W. (1971). A cooperative evaluation of test systems used to assay tuberculosis vaccines. Bull. World Health Organ. 45:543–550.PubMedGoogle Scholar
  31. 31.
    Anon. (1955). Experimental studies of vaccination, allergy, and immunity in tuberculosis. V. Relation between degree of tuberculin sensitivity and resistance in the vaccinated individual. Amer. J. Hyg. 62:185–189.Google Scholar
  32. 32.
    Bullock, W.E. (1975). Anergy and infection. Adv. Internal Med. 21:149–173.Google Scholar
  33. 33.
    Godai, T. (1978). Immunological aspects of leprosy-present status. Prog. Allergy. 25:211–242.Google Scholar
  34. 34.
    Lurie, M.G., Abramson, S. and Heppleton, A.G. (1952). On the response of genetically resistant and susceptible rabbits to the qualitative inhalation of human type tubercle bacilli and the nature of resistance to tuberculosis. J. Exp. Med. 95:119–134.PubMedCrossRefGoogle Scholar
  35. 35.
    Gray, D.F. (1961). The relative natural resistance of rats and mice to experimental pulmonary tuberculosis. J. Hyg. 59:471–477.CrossRefGoogle Scholar
  36. 36.
    Youmans, G.P., Youmans, A.S. and Kanai, K. (1959). The difference in response of four strains of mice to immunization against tuberculous infection. Amer. Rev, Tuberc. 80:753–756.Google Scholar
  37. 37.
    Forget, A., Skamene, E., Gros, P.K., Miailhe, A.C. and Turcotte, R. (1981). Differences in response among inbred mouse strains to infection with small doses of Mycobacterium bovis BCG. Inf. Immun. 32:42–47.Google Scholar
  38. 38.
    Allen, E.M., Morre, V.L. and Stevens, J.O. (1977). Strain variation in BCG-induced chronic pulmonary inflammation in mice. 1. Basic model and possible genetic control by non H-2 genes. J. Immunol. 196:343–347.Google Scholar
  39. 39.
    Daniel, R.M. (1980). The immunology of tuberculosis. Clinics Chest Med. 1:189–201.Google Scholar
  40. 40.
    Lurie, M.B. (1964). Resistance to tuberculosis: experimental studies in native and acquired defense mechanisms. Harvard Univ. Press, Cambridge, Mass.Google Scholar
  41. 41.
    Weigeshaus, E.H. and Smith, D.W. (1968). Experimental models for study of immunity in tuberculosis. Ann. N.Y. Acad. Sci. 154:174–199.Google Scholar
  42. 42.
    Collins, F.M. (1972). Acquired resistance to mycobacterial infections. Adv. Tuberc. Res. 18:1–30.Google Scholar
  43. 43.
    Collins, F.M., Wayne, L.G. and Montalbine, V. (1974). The effect of cultural conditions on the distribution of Mycobacterium tuberculosis in the spleens of specific pathogen-free mice. Amer. Rev. Resp. Dis. 110:147–156.PubMedGoogle Scholar
  44. 44.
    Kim, T.H. and Kubica, G.P. (1972). Long term preservation and storage of mycobacteria. Appl. Microbiol. 24:311–317.PubMedGoogle Scholar
  45. 45.
    Collins, F.M., Morrison, N.E. and Montalbine, V. (1978). Immune response to persistent mycobacterial infection in mice. Infec. Immun. 20:430–438.Google Scholar
  46. 46.
    Blanden, R.V., Lefford, M.J. and Mackaness, G.B. (1969). The host response to Calmette-Guerin bacillus infection in mice. J. Exp. Med. 129:1079–1107.PubMedCrossRefGoogle Scholar
  47. 47.
    Lefford, M.J. (1975). Transfer of adoptive immunity to tuberculosis in mice. Immunol. 21:369–381.Google Scholar
  48. 48.
    Collins, F.M. and Mackaness, G.B. (1970). The relationship of delayed hypersensitivity to acquired antituberculous immunity. 1. Tuberculin sensitivity and resistance to reinfection in BCG-vaccinated mice. Cell. Immunol. 1: 253–265.PubMedCrossRefGoogle Scholar
  49. 49.
    Wiegeshaus, E.H., McMurray, D.N., Grover, A.A., Harding, G.E. and Smith, D.W. (1970). Host-parasite relationships in experimental airborne tuberculosis. III. Relevance of microbial enumeration to acquired resistance in guinea pigs. Amer. Rev. Resp. Dis. 102:422–429.PubMedGoogle Scholar
  50. 50.
    Fok, J.S., Ho, R.S., Arora, K., Harding, G.E. and Smith, D.W. (1976). Host-parasite relationships in experimental tuberculosis. V. Lack of hematogenous dissemination of M. tuberculosis to the lungs in animals vaccinated with Bacille Calmette-Guerin. J. Inf. Dis. 133:137–144.CrossRefGoogle Scholar
  51. 51.
    Collins, F.M. (1979). Cellular antimicrobial immunity. Crit. Rev. Microbiol. 7:27–91.CrossRefGoogle Scholar
  52. 52.
    Mackaness, G.B. (1971). The induction and expression of cellmediated hypersensitivity in the lung. Amer. Rev. Resp, Dis. 104:813–828.Google Scholar
  53. 53.
    Collins, F.M. (1971). Mechanisms in antimicrobial immunity. J. Reticuloendothel. Soc. 10:58–99.PubMedGoogle Scholar
  54. 54.
    McCune, R.M., Feldman, F.M. and McDermott, W. (1966), Microbial persistence II. Characteristics of the sterile state of tubercle bacilli. J. Exp. Med. 123:469–486.PubMedCrossRefGoogle Scholar
  55. 55.
    Collins, F.M. (1973). The relative immunogenic of virulent and attenuated strains of tubercle bacilli. Amer. Rev. Resp. Dis. 107:1030–1040.PubMedGoogle Scholar
  56. 56.
    Lefford, M.J., McGregor, D.D. and Mackaness, G.B. (1973). Immune response to M. tuberculosis in rats. Inf. Immun. 8:182–189.Google Scholar
  57. 57.
    Reggiardo, Z. and Middlebrook, G. (1974). Failure of passive serum transfer of immunity against aerogenic tuberculosis in guinea pigs. Proc. Soc. Exp. Biol. Med. 145:173–175.PubMedGoogle Scholar
  58. 58.
    North, R.J. (1973). Importance of thymus derived lymphocytes in cell-mediated immunity to infection. Cell.Immun. 7: 166–176.CrossRefGoogle Scholar
  59. 59.
    Collins, F.M., Congdon, C.C. and Morrison, N.E. (1975). Growth of Mycobacterium bovis (BCG) in T-lymphocyte depleted mice. Infec. Immun. 11:57–64.Google Scholar
  60. 60.
    Morrison, N.E. and Collins, F.M. (1975). Immunogenicity of an aerogenic BCG vaccine in T-cell depleted and normal mice. Inf. Immun. 11:1110–1121.Google Scholar
  61. 61.
    Collins, F.M. and Auclair, L.K. (1979). Effect of thymosin treatment on anti-tuberculous immunity in immunosuppressed mice. J. Reticulendothelial Soc. 26:143–153.Google Scholar
  62. 62.
    Bach, J.F. (1976). The mode of action of thymic hormones and its relevance to T-cell differentiation. Transplant. Proc. 8:243–248.PubMedGoogle Scholar
  63. 63.
    Collins, F.M. and Morrison, N.E. (1979). Restoration of T-cell responsiveness to thymosin: expression of anti-tuberculous immunity in mouse lung. Inf. Immun. 23: 330–335.Google Scholar
  64. 64.
    Mackaness, G.B. (1974). Delayed hypersensitivity in lung disease. Ann. N.Y. Acad. Sci. 221:312–316.PubMedCrossRefGoogle Scholar
  65. 65.
    North, R.J. (1974). T-cell dependence of macrophage activation and mobilization during infection with Mycobacterium tuberculosis. Infect. Immun. 10:66–71.PubMedGoogle Scholar
  66. 66.
    Collins, F.M., Auclair, L.K. and Mackaness, G.B. (1977). Mycobacterium bovis (BCG) infection of the lymph nodes of normal, immune and cortisone-treated guinea pigs. J. Natl. Cancer Inst. 59:1527–1535.PubMedGoogle Scholar
  67. 67.
    Rooney, J.J., Croceo, J.A. and Kramer, S. (1976). Further observations on tuberculin reactions in active tuberculosis. Amer. J. Med. 60:517–522.PubMedCrossRefGoogle Scholar
  68. 68.
    Collins, F.M. (1971). Immunogenicity of various mycobacteria and the corresponding levels of cross-protection developed between species. Infec. Immun. 4:688–696.Google Scholar
  69. 69.
    Watson, S.R., Morrison, N.E. and Collins, F.M. (1979). Delayed hypersensitivity responses to Mycobacterium leprae M. vaccae and M. nonchromogenicum cytoplasmic proteins. Inf. Immun. 25:229–236.Google Scholar
  70. 70.
    Watson, S.R. and Collins, F.M. (1980). Development of suppressor T cells in mice heavily infected with mycobacteria. Immunol. 39:367–373.Google Scholar
  71. 71.
    Collins, F.M. and Watson, S.R. (1979). Suppressor T-cells in BCG-infected mice. Infec. Immun. 25:491–496.Google Scholar
  72. 72.
    Watson, S.R. and Collins, F.M. (1979). The development of suppressor T-cells in Mycobacterium habana-infected mice. Inf. Immun. 25:497–506.Google Scholar
  73. 73.
    Parish, C.R. (1972). The relationship between humoral and cell-mediated immunity. Transplant. Rev. 13:35–66.PubMedGoogle Scholar
  74. 74.
    Uberoi, S., Malairga, A.N., Chatopadhyay, C., Kamar, R. and Shrivias, X. (1975). Secondary immunodeficiency in miliary tuberculosis. Clin. Exp. Immunol. 22:404–408.PubMedGoogle Scholar
  75. 75.
    Bullock, W.E. (1978). Leprosy: a model of immunological perturbation in chronic infection. J. Inf. Dis. 137:341–354.CrossRefGoogle Scholar
  76. 76.
    Godal, T., Myrvang, B., Forhland, S.S., Shao, J. and Melaku, G. (1972). Evidence that the mechanism of immunological tolerance (central failure) is operative in the lack of host resistance in lepromatous leprosy. Scand. J. Immunol. 4:311–321.CrossRefGoogle Scholar
  77. 77.
    Rook, G.A.W. (1975). The immunological consequences of antigen overload in experimental mycobacterial infections mice. Clin. Exp. Immunol. 19:167–178.PubMedGoogle Scholar
  78. 78.
    Nyka, W. (1963). Studies on M. tuberculosis in lesions in human lung. Amer. Rev. Resp. Dis. 88:670–679.PubMedGoogle Scholar
  79. 79.
    Sutter, E. and Roulet, F.C. (1968). Staining M. leprae in paraffin sections by the Gomori methenamine-silver method. Stain Technol. 40:49–51.Google Scholar
  80. 80.
    Watson, S.R. and Collins, F.M. (1981). The specificity of suppressor T-cells induced by Mycobacterium avium infections in mice. Clin. Exp. Immunol. 43:10–19.PubMedGoogle Scholar
  81. 81.
    Bast, R.C., Bast, B.S. and Raff, H.J. (1976). Critical review of previously reported animal studies of tumor immunotherapy with non-specific immunostimulants. Annals N.Y. Acad. Sci. 277:60–92.CrossRefGoogle Scholar
  82. 82.
    Mastrangelo, M.J., Berd, D. and Beller, R.E. (1976). Critical review of previously reported clinical trials of cancer immunotherapy with non-specific immunostimulants. Annals N.Y. Acad. Sci. 277:94–123.CrossRefGoogle Scholar
  83. 83.
    Mathé, G. (1976). Surviving in company of BCG. Cancer Immunol. Immunother. 1:3–6.Google Scholar
  84. 84.
    Portelance, V., Quevillan, M. and Page, Y. (1976). Toxic effects of massive doses of BCG in mice, guinea pigs and monkeys. Cancer Immunol. Immunother. 1:63–68.CrossRefGoogle Scholar
  85. 85.
    Gefford, M. and Orbach-Arbouys, S. (1976). Enhancement of suppressor activity in mice by high doses of BCG. Cancer Immunol. Immunother. 1:41–44.Google Scholar
  86. 86.
    Klimpel, G.R. and Henny, C.S. (1978). BCG-induced suppressor cells. 1. Demonstration of a macrophage-like suppressor cell that inhibits cytoxic T-cell generation. J. Immunol. 12:563–569.Google Scholar
  87. 87.
    Cantor, H. (1979). Control of the immune system by inhibitor and inducer T-lymphocytes. Ann Rev. Med. 30:269–278.PubMedCrossRefGoogle Scholar
  88. 88.
    Collins, F.M. and Watson, S.R. (1980). Effect of chemotherapy on suppressor T-cells in BCG-infected mice. Immunol. 40:529–537.Google Scholar
  89. 89.
    Lenzini, L., Rottoli, P. and Rottoli, L. (1977). The spectrum of human tuberculosis. Clin. Exp. Immunol. 27:230–237.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • Frank M. Collins
    • 1
  1. 1.Trudeau Institute, Inc.Saranac LakeUSA

Personalised recommendations